Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.

Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.

Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.

Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.

Abstract: Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide comprising an amino acid sequence depicted in any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide comprising an amino acid sequence depicted in any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

Abstract: The present invention relates to PPAR?-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR?-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR?-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention provides an oral preventive or therapeutic agent for skin damage, containing diacylglyceryl ether as an active ingredient represented by the formula (I): wherein R1 denotes C12-24 aliphatic hydrocarbon group having a degree of unsaturation of between 0 and 2; R2 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6; and R3 denotes C12-24 acyl group having a degree of unsaturation of between 0 and 6.

Abstract: A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: wherein A represents an optionally substituted CH3CnH(2n-2m)— (wherein n denotes an integer of 4 to 22, and m represents an unsaturation number which is an integer of 0 to 7), l represents an integer of 0 to 10, s represents 0 or 1, provided that when s is 0, p+q=4 or 5, but when s is 1, p+q=3 or 4, and in each case, either p or q is an integer of 1 or more, R represents an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and RA represents hydrogen or an alkyl group having 1 to 10 carbon atoms which may be straight-chain or branched-chain, and their use in suppression of platelet aggregation, in suppression of inflammation, and in prevention and treatment of circulatory diseases.

Abstract: Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof

Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: where n denotes an integer of 1 to 11, and 1 denotes an integer of 1 to 16, the aliphatic compound being an optical isomer of the (2R,3S,2′S) configuration when the 8-position thereof is a double bond, or an optical isomer of the (2S,3R,2′RS) configuration when the 8-position is a single bond; methods for producing the compound or pharmacologically acceptable salts thereof; and uses of the compound in the treatment of cardiovascular diseases (e.g. arteriosclerosis, cardiac diseases), cancer, rheumatism, diabetic retinopathy, and respiratory diseases.

Abstract: The present invention relates to PPAR&ggr;-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPAR&ggr;-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, as well as uses of the PPAR&ggr;-activating pharmaceutical compositions for treating circulatory diseases, arteriosclerosis, lipid metabolism disorder, diabetes and inflammatory diseases.

Abstract: The present invention relates to aliphatic compounds of the formula I, or stereoisomers thereof, or their pharmaceutically acceptable salts: 1

Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: 1

Abstract: {circle around (1)} Compounds of the following general formula (1) having a glucuronic acid derivative and a glucosamine derivative in the structure thereof, pharmacologically acceptable salts and solvates of the compounds, or solvates of the salts, {circle around (2)} a method for producing the compounds {circle around (1)}, {circle around (3)} a pharmaceutical composition containing the compounds {circle around (1)}, {circle around (4)} polymers having at least one of the compounds {circle around (1)} as a side chain structure, {circle around (5)} a coating agent containing the compound {circle around (1)} or the polymer as one of active ingredients, and {circle around (6)} molded products, artificial organs, medical devices, and equipment for cell culture, which have been produced using the polymer {circle around (4)} and/or the coating agent {circle around (5)}.

Abstract: The present invention provides cell lines capable of indefinite growth which are produced by transforming leukocytes isolated from peripheral blood of fish with a oncogene, a method of establishing the cell line, a method of recovering immunologically active substances from the culture of the cell lines. It has been difficult to maintain continuous cultures of fish leukocytes. The present invention provides cell lines capable of indefinite growth and a method of producing immunologically active substances, e.g., immunologically acitive substances, using these cell lines.